BioMarin Pharmaceutical Inc. · BMRN · FY2026 Q1 · Calendar Q2 2026
BioMarin raises 2026 revenue outlook after Amicus acquisition
The raised 2026 revenue outlook and added Amicus products support a stronger growth case, while acquisition integration, modest near-term EPS dilution, competitive pressure and legal and regulatory uncertainty remain important counterweights.
Earnings scorecard
Reported versus consensusMarket reaction
event-close to next-session closeAsk FN2 about BMRN FY2026 Q1
Transcript, numbers and history already loadedFree account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
BioMarin completed its Amicus Therapeutics acquisition, adding Galafold, Pombility and Opfolda. Management raised full-year revenue and Enzyme Therapies guidance and described strong Voxzogo patient-start momentum. The reported quarter beat revenue estimates but came in slightly below the EPS estimate.
Guidance delta
Management raised full-year 2026 revenue guidance to $3.825–$3.925 billion and Enzyme Therapies guidance to $2.725–$2.775 billion. The acquisition is expected to be slightly dilutive to 2026 EPS and accretive after the first twelve months.
Key takeaways
- The Amicus acquisition adds Galafold, Pombility and Opfolda to the portfolio and underpins management’s higher 2026 revenue outlook.
- Management cited more than 20% year-over-year growth in new Voxzogo patient starts, with focus on children under two.
- Q1 revenue was above the estimate, while EPS was slightly below the estimate.
- Management identified Q2 for further Amicus integration detail and pipeline updates, including Voxzogo hypochondroplasia and BMN-401.
Management priorities
- Integrate Amicus and provide a detailed integration roadmap and commercial strategy.
- Expand Pombility internationally toward an 80-country footprint.
- Advance Voxzogo approval and launch preparations for hypochondroplasia.
- Deliver expected clinical updates for Voxzogo hypochondroplasia and BMN-401.
Follow BMRN with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeCompany context
Snapshot as of publicationBioMarin Pharmaceutical Inc. specializes in creating and bringing to market treatments for individuals suffering from severe and often fatal rare disorders and other critical medical conditions. The company currently markets several key pharmaceutical products. Among these are Vimizim, an enzyme replacement therapy targeting mucopolysaccharidosis (MPS) IV type A, a specific lysosomal storage disorder, and Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for individuals with MPS VI. Another notable offering is Kuvan, a unique synthetic oral version of 6R-BH4, prescribed for phenylketonuria (PKU), an inherited metabolic condition. Further expanding its product portfolio, BioMarin provides Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme administered via subcutaneous injection to lower blood Phe levels.…
Historical context
All BMRN earningsHealthcare peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| VRTX Vertex Pharmaceuticals Incorporated | FY2026 Q3 · Calendar Q4 2026 | -1.2% | -1.0% | Vertex lifts 2026 outlook as CF franchise and newer products support growth |
| JAZZ Jazz Pharmaceuticals plc | FY2026 Q3 · Calendar Q4 2026 | +4.2% | -0.7% | Jazz lifts 2026 revenue outlook as Ziihera launch adds momentum |
| IDXX IDEXX Laboratories, Inc. | FY2026 Q3 · Calendar Q4 2026 | +6.2% | +21.8% | IDEXX Raises FY2026 Outlook on Diagnostics and Software Growth |
| NBIX Neurocrine Biosciences, Inc. | FY2026 Q3 · Calendar Q4 2026 | +72.3% | -0.5% | Neurocrine Raises INGREZZA Outlook as Core Products Grow |
| AXSM Axsome Therapeutics, Inc. | FY2026 Q3 · Calendar Q4 2026 | +60.6% | -5.8% | Axsome’s Q3 growth broadens, while reimbursement and trial execution remain key tests |
| TEM Tempus AI, Inc. | FY2026 Q3 · Calendar Q4 2026 | +174.7% | +8.7% | Tempus Q3 growth broadens across diagnostics and data |
Latest beats and misses
Who reports nextBeat on EPS
- TSEMFY2026 Q3 · November 2, 2026+7.5% EPS-6.7% move
- CLXFY2027 Q1 · November 2, 2026+44.9% EPS+2.2% move
- AAPLFY2026 Q4 · November 2, 2026+3.0% EPS-1.8% move
- PLTRFY2026 Q3 · November 2, 2026+8.3% EPS-3.1% move
- ETRFY2026 Q3 · November 2, 2026+14.5% EPS-0.2% move
- OFY2026 Q3 · November 2, 2026+5.7% EPS+1.1% move
Missed on EPS
- VRTXFY2026 Q3 · November 2, 2026-1.2% EPS-1.0% move
- PEGFY2026 Q3 · November 2, 2026-3.4% EPS+0.1% move
- RYAAYFY2027 Q2 · November 2, 2026-0.3% EPS+2.9% move
- GLPIFY2026 Q3 · October 29, 2026-11.5% EPS-1.3% move
- LYBFY2026 Q3 · October 30, 2026-1.2% EPS+5.0% move
- CCJFY2026 Q3 · October 30, 2026-101.4% EPS-7.9% move
Get the BMRN recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
- FN2 earnings calendar · 2026-07-26T00:37:12.209961+00:00
- Polygon adjusted daily market bars · 2026-11-03T09:40:46.823083+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-11-03T09:40:46.820311+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-11-03. For educational purposes only; not investment advice.